Skip to content
Webe Honey – Lifestyle
Home
Sample Page
Author:
GENFIT S.A.
GENFIT: NASHnext®, Powered by GENFIT’s Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 8, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 25, 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
May 21, 2026
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
May 11, 2026
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
April 20, 2026
GENFIT Announces Publication of the 2025 Universal Registration Document
April 7, 2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
March 9, 2026